TNFRSF17 and infection: These findings demonstrate the fast-acting and highly specific nature of IBI379, as it selectively targets pathogenic plasma cells expressing TNFRSF17 while preserving the patient’s B cell immune defense against infections, thus minimizing the risk of severe adverse reactions.